Investigational drug · Phase 2
SAB-142
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Type 1 Diabetes.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SAB-142"
First trial start
2025
Nov 25, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SAB-142", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 1 Diabetes
Approved drugs for the same conditions: Type 1 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "SAB-142" as an intervention, largest first.
- SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 DiabetesPivotal-lookingRecruiting
SAb Biotherapeutics, Inc.Industry
NCT07187531 · 159 participants (planned) · Start Nov 25, 2025 · Primary completion Nov 2027
Drug: High Dose SAB-142; Low Dose SAB-142 · For: Type 1 Diabetes
Sites: San Francisco, California; San Jose, California; Aurora, Colorado · 68 sites in all
- PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) StudyPivotal-lookingRecruiting
University of FloridaAcademic, hospital or other
NCT07670650 · 108 participants (planned) · Start Nov 10, 2026 · Primary completion Mar 1, 2029
Drug: SAB-142; Placebo · For: Type 1 Diabetes (T1D)
Sites: San Francisco, California; Aurora, Colorado; Gainesville, Florida · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Type 1 Diabetes
- THDB0206Phase 32 trials
Tonghua Dongbao Pharmaceutical Co.,Ltd · Type 2 Diabetes, Type 1 Diabetes
- ZimislecelFormerly known as STx-02, VX-880Phase 32 trials
Vertex Pharmaceuticals · Type 1 Diabetes, Kidney Transplant, Diabetes Mellitus, Type 1
- CNP-103Phase 21 trial
COUR Pharmaceutical Development Company, Inc. · Type 1 Diabetes Mellitus, T1D, T1DM
- VX-264Phase 21 trial
Vertex Pharmaceuticals · Type 1 Diabetes
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.